1
|
Argentova V, Aliev T, Dolgikh D, Pakanová Z, Katrlík J, Kirpichnikov M. Features, modulation and analysis of glycosylation patterns of therapeutic recombinant immunoglobulin A. Biotechnol Genet Eng Rev 2022; 38:247-269. [PMID: 35377278 DOI: 10.1080/02648725.2022.2060594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Increasing the production of recombinant antibodies while ensuring high and stable protein quality remains a challenge in mammalian cell culture. This review is devoted to advances in the field of obtaining stable and optimal glycosylation of therapeutic antibodies based on IgA, as well as the subsequent issues of glycosylation control of glycoproteins during their production. Current studies also demonstrate a general need for a more fundamental understanding of the use of CHO cell-based producer cell lines, through which the glycoprofile of therapeutic IgA antibodies is produced and the dependence of glycosylation on culture conditions could be controlled. Optimization of glycosylation improves the therapeutic efficacy and can expand the possibilities for the creation of highly effective glycoprotein therapeutic drugs. Current status and trends in glycan analysis of therapeutic IgA, dominantly based on mass spectrometry and lectin microarrays are herein summarised as well.
Collapse
Affiliation(s)
- Victoria Argentova
- Department of Bioengineering, School of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Teimur Aliev
- Department of Chemical Enzymology, School of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Dmitry Dolgikh
- Department of Bioengineering, School of Biology, Lomonosov Moscow State University, Moscow, Russia.,Institute of Bioorganic Chemistry, Russian Academy of SciencesShemyakin-Ovchinnikov, Moscow, Russia
| | - Zuzana Pakanová
- Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia
| | - Jaroslav Katrlík
- Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia
| | - Mikhail Kirpichnikov
- Department of Bioengineering, School of Biology, Lomonosov Moscow State University, Moscow, Russia.,Institute of Bioorganic Chemistry, Russian Academy of SciencesShemyakin-Ovchinnikov, Moscow, Russia
| |
Collapse
|
2
|
Puranik A, Saldanha M, Chirmule N, Dandekar P, Jain R. Advanced strategies in glycosylation prediction and control during biopharmaceutical development: Avenues toward Industry 4.0. Biotechnol Prog 2022; 38:e3283. [PMID: 35752935 DOI: 10.1002/btpr.3283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 05/31/2022] [Accepted: 06/17/2022] [Indexed: 11/09/2022]
Abstract
Glycosylation has been shown to define the safety and efficacy of biopharmaceuticals, thus classified as a critical quality attribute. However, controlling glycan heterogeneity has always been a major challenge owing to the multi-variate factors that govern the glycosylation process. Conventional approaches for controlling glycosylation such as gene editing and metabolic control have succeeded in obtaining desired glycan profiles in accordance with the Quality by Design paradigm. Nonetheless, the development of smart algorithms and omics-enabled complete cell characterization have made it possible to predict glycan profiles beforehand, and manipulate process variables accordingly. This review thus discusses the various approaches available for control and prediction of glycosylation in biopharmaceuticals. Further, the futuristic goal of integrating such technologies is discussed in order to attain an automated and digitized continuous bioprocess for control of glycosylation. Given, control of a process as complex as glycosylation requires intense monitoring intervention, we examine the current technologies that enable automation. Finally, we discuss the challenges and the technological gap that currently limits incorporation of an automated process in routine bio-manufacturing, with a glimpse into the economic bearing. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Amita Puranik
- Department of Chemical Engineering, Institute of Chemical Technology, Matunga, Mumbai, India
| | - Marianne Saldanha
- Department of Chemical Engineering, Institute of Chemical Technology, Matunga, Mumbai, India
| | | | - Prajakta Dandekar
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, India
| | - Ratnesh Jain
- Department of Chemical Engineering, Institute of Chemical Technology, Matunga, Mumbai, India
| |
Collapse
|
3
|
Beauglehole AC, Roche Recinos D, Pegg CL, Lee YY, Turnbull V, Herrmann S, Marcellin E, Howard CB, Schulz BL. Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering. Crit Rev Biotechnol 2022; 43:484-502. [PMID: 35430942 DOI: 10.1080/07388551.2022.2036691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Appropriate treatment of Hemophilia B is vital for patients' quality of life. Historically, the treatment used was the administration of coagulation Factor IX derived from human plasma. Advancements in recombinant technologies allowed Factor IX to be produced recombinantly. Successful recombinant production has triggered a gradual shift from the plasma derived origins of Factor IX, as it provides extended half-life and expanded production capacity. However, the complex post-translational modifications of Factor IX have made recombinant production at scale difficult. Considerable research has therefore been invested into understanding and optimizing the recombinant production of Factor IX. Here, we review the evolution of recombinant Factor IX production, focusing on recent developments in bioprocessing and cell engineering to control its post-translational modifications in its expression from Chinese Hamster Ovary (CHO) cells.
Collapse
Affiliation(s)
- Aiden C. Beauglehole
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
- CSL Innovation, Parkville, Victoria, Australia
| | - Dinora Roche Recinos
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
- CSL Innovation, Parkville, Victoria, Australia
| | - Cassandra L. Pegg
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia
| | | | - Victor Turnbull
- CSL Innovation, Bio21 Institute of Molecular Science and Biotechnology, Parkville, Victoria, Australia
| | - Susann Herrmann
- CSL Innovation, Bio21 Institute of Molecular Science and Biotechnology, Parkville, Victoria, Australia
| | - Esteban Marcellin
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
| | - Christopher B. Howard
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
| | - Benjamin L. Schulz
- ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, QLD, Australia
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia
| |
Collapse
|
4
|
|
5
|
Stone AT, Dhara VG, Naik HM, Aliyu L, Lai J, Jenkins J, Betenbaugh MJ. Chemical speciation of trace metals in mammalian cell culture media: looking under the hood to boost cellular performance and product quality. Curr Opin Biotechnol 2021; 71:216-224. [PMID: 34478939 DOI: 10.1016/j.copbio.2021.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 07/17/2021] [Accepted: 08/04/2021] [Indexed: 01/06/2023]
Abstract
Upstream process development seeks to optimize media formulations to promote robust cell culture conditions and regulate product quality attributes such as glycosylation, aggregation, and charge variants. Transition metal ions Mn, Fe, Cu, and Zn present in cell culture media have a significant impact on cell growth, metabolism and product quality. These metals and other media components can have different chemical associations or speciation in media that are poorly characterized but may significantly impact their properties and effect on cellular performance. Computer-based equilibrium models are a good starting point for exploring metal speciation, bioavailability and conditions where precipitation may occur. However, some equilibrium constants, especially for newly introduced medium components, have not been experimentally determined. Owing to concurrent physical and biological processes, speciation may also be controlled by reaction kinetics rather than by equilibrium. These factors highlight the importance of analytically interrogating medium speciation to gain insights into the complex interconnections between media components and bioprocess performance.
Collapse
Affiliation(s)
- Alan T Stone
- Department of Environmental Health and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Venkata Gayatri Dhara
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Harnish Mukesh Naik
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Lateef Aliyu
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Junxi Lai
- Department of Environmental Health and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Jackson Jenkins
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Michael J Betenbaugh
- Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
| |
Collapse
|
6
|
Fung Shek C, Kotidis P, Betenbaugh M. Mechanistic and data-driven modeling of protein glycosylation. Curr Opin Chem Eng 2021. [DOI: 10.1016/j.coche.2021.100690] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
7
|
Weiss CH, Merkel C, Zimmer A. Impact of iron raw materials and their impurities on CHO metabolism and recombinant protein product quality. Biotechnol Prog 2021; 37:e3148. [PMID: 33742789 PMCID: PMC8459231 DOI: 10.1002/btpr.3148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 01/31/2021] [Accepted: 02/28/2021] [Indexed: 12/12/2022]
Abstract
Cell culture medium (CCM) composition affects cell growth and critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and recombinant proteins. One essential compound needed within the medium is iron because of its central role in many cellular processes. However, iron is also participating in Fenton chemistry leading to the formation of reactive oxygen species (ROS) causing cellular damage. Therefore, this study sought to investigate the impact of iron in CCM on Chinese hamster ovary (CHO) cell line performance, and CQAs of different recombinant proteins. Addition of either ferric ammonium citrate (FAC) or ferric citrate (FC) into CCM revealed major differences within cell line performance and glycosylation pattern, whereby ammonium was not involved in the observed differences. Inductively coupled plasma mass spectrometry (ICP‐MS) analysis identified varying levels of impurities present within these iron sources, and manganese impurity rather than iron was proven to be the root cause for increased cell growth, titer, and prolonged viability, as well as altered glycosylation levels. Contrary effects on cell performance and protein glycosylation were observed for manganese and iron. The use of low impurity iron raw material is therefore crucial to control the effect of iron and manganese independently and to support and guarantee consistent and reproducible cell culture processes.
Collapse
Affiliation(s)
- Christine H Weiss
- Merck Life Science, Upstream R&D, Darmstadt, Germany.,Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | | | - Aline Zimmer
- Merck Life Science, Upstream R&D, Darmstadt, Germany
| |
Collapse
|
8
|
Villacrés C, Tayi VS, Butler M. Strategic feeding of NS0 and CHO cell cultures to control glycan profiles and immunogenic epitopes of monoclonal antibodies. J Biotechnol 2021; 333:49-62. [PMID: 33901620 DOI: 10.1016/j.jbiotec.2021.04.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 04/03/2021] [Accepted: 04/18/2021] [Indexed: 01/12/2023]
Abstract
The control of glycosylation profiles is essential to the consistent manufacture of therapeutic monoclonal antibodies that may be produced from a variety of cell lines including CHO and NS0. Of particular concern is the potential for generating non-human epitopes such as N-glycolylneuraminic acid (Neu5Gc) and Galα1-3 Gal that may be immunogenic. We have looked at the effects of a commonly used media supplements of manganese, galactose and uridine (MGU) on Mab production from CHO and NS0 cells in enhancing galactosylation and sialylation as well as the generation of these non-human glycan epitopes. In the absence of the MGU supplement, the humanized IgG1 antibody (Hu1D10) produced from NS0 cells showed a low level of mono- and di-sialylated structures (SI:0.09) of which 75 % of sialic acid was Neu5Gc. The chimeric human-llama Mab (EG2-hFc) produced from CHO cells showed an equally low level of sialylation (SI: 0.12) but the Neu5Gc content of sialic acid was negligible (<3%). Combinations of the MGU supplements added to the production cultures resulted in a substantial increase in the galactosylation of both Mabs (up to GI:0.78 in Hu1D10 and 0.81 in EG2-hFc). However, the effects on sialylation differed between the two Mabs. We observed a slight increase in sialylation of the EG2-hFc Mab by a combination of MG but it appeared that one of the components (uridine) was inhibitory to sialylation. On the other hand, MG or MGU increased sialylation of Hu1D10 substantially (SI:0.72) with an increase that could be attributed predominantly to the formation of Neu5Ac rather than Neu5Gc. The increased level of galactosylation observed with MG or MGU was attributed to an activation of the galactosyl transferase enzymes through enhanced intracellular levels of UDP-Gal and the availability of Mn2+ as an enzymic co-factor. However, this effect not only increased the desirable beta 1-4 Gal linkage to GlcNAc but unfortunately in NS0 cells increased the formation of Galα1-3 Gal which was shown to increase x3 in the presence of combinations of the MGU supplements. Supplementation of media with fetal bovine serum (FBS) increased the availability of free Neu5Ac which resulted in a significant increase in the sialylation of Hu1D10 from NS0 cells. This also resulted in a significant decrease in the proportion of Neu5Gc in the measured sialic acid from the Mab.
Collapse
Affiliation(s)
- Carina Villacrés
- Department of Microbiology, University of Manitoba, Winnipeg, MB, R3T2N2, Canada
| | - Venkata S Tayi
- Department of Microbiology, University of Manitoba, Winnipeg, MB, R3T2N2, Canada
| | - Michael Butler
- Department of Microbiology, University of Manitoba, Winnipeg, MB, R3T2N2, Canada; National Institute for Bioprocessing Research & Training (NIBRT), Fosters Avenue, Dublin, A94 X099, Ireland.
| |
Collapse
|
9
|
Xu J, Shao Z, Han X, Huang Y, Zou X, Shen Y. Similarity assessment by multivariate statistics method based on the distance between biosimilar and originator. BIORESOUR BIOPROCESS 2021; 8:24. [PMID: 38650220 PMCID: PMC10992075 DOI: 10.1186/s40643-021-00378-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 03/16/2021] [Indexed: 12/26/2022] Open
Abstract
The development of biosimilar products or follow-on biologics has been flourishing in recent years because of their lower price than the originators. In this study, a multivariate data analysis method based on JMP software was proposed to assess the glycosylation pattern similarity of antibody candidates from different conditions in optimization experiments with a reference. A specific distance was generated by this method and indicated the glycoform similarity between the biosimilar and the reference. This method can be applied to analyze the similarity of other physicochemical and functional characteristics between follow-on biologics and originators. Then, the design of experimental methods can be realized to optimize the conditions of cell culture to attain similar antibody candidates. A higher concentration of GlcNAc added to the basal media made the glycan of the antibody more similar to the glycan of the reference in this study.
Collapse
Affiliation(s)
- Jian Xu
- State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, 130 Mei Long Road, Shanghai, 200237, China
| | - Zhihui Shao
- CAS Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China
| | - Xiaoxiong Han
- Process Development Department, Dragon Sail Pharmaceutical, Shanghai, China
| | - Yingfeng Huang
- R&D Laboratories, Dragonboat Biopharmaceutical, Shanghai, China
| | - Xun Zou
- Shanghai Sanjin Bioscience and Technology, Shanghai, China
| | - Yaling Shen
- State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, 130 Mei Long Road, Shanghai, 200237, China.
| |
Collapse
|
10
|
Komuczki D, Dutra G, Gstöttner C, Dominguez-Vega E, Jungbauer A, Satzer P. Media on-demand: Continuous reconstitution of a chemically defined media directly from solids. Biotechnol Bioeng 2021; 118:3382-3394. [PMID: 33656168 PMCID: PMC8451748 DOI: 10.1002/bit.27738] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 01/26/2021] [Accepted: 02/19/2021] [Indexed: 12/15/2022]
Abstract
Chemically defined media are reconstituted batchwise and stored in hold tanks until use. To avoid large hold tanks and batchwise production of media, we developed continuous on‐demand reconstitutions directly from solids consisting of a hopper and a screw conveyor capable of feeding dry powdered media with the required precision ±5% at low dosing rates of 0.171 g min−1. A commercially available dry powdered cell culture medium was continuously fed over a duration of 12 h into a mixer which was connected to a UV‐cell for monitoring and the media were compared to a batchwise production. A comparable amino acid, carbohydrate, and osmolality profile to a batchwise reconstitution could be obtained. Cell cultivation showed comparable performance of batch and continuous reconstitution for two CHO cell lines producing the antibodies adalimumab and trastuzumab on a small and benchtop scale. In‐depth analysis of the produced antibodies showed the same glycosylation pattern, other posttranslational profiles such as methionine oxidation and deamidation compared to batchwise reconstitution. Therefore, we conclude a continuous reconstitution of the medium results in the same quality of the product. A continuous on‐demand media reconstitution will impact the supply chain and significantly reduce the floor space necessary for preparation and storage.
Collapse
Affiliation(s)
- Daniel Komuczki
- Department of Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Gregory Dutra
- Department of Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Christoph Gstöttner
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
| | - Elena Dominguez-Vega
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
| | - Alois Jungbauer
- Department of Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria.,Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Peter Satzer
- Department of Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria.,Austrian Centre of Industrial Biotechnology, Vienna, Austria
| |
Collapse
|
11
|
Madabhushi SR, Podtelezhnikov AA, Murgolo N, Xu S, Lin H. Understanding the effect of increased cell specific productivity on galactosylation of monoclonal antibodies produced using Chinese hamster ovary cells. J Biotechnol 2021; 329:92-103. [PMID: 33549674 DOI: 10.1016/j.jbiotec.2021.01.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Revised: 01/12/2021] [Accepted: 01/31/2021] [Indexed: 12/22/2022]
Abstract
Achieving optimal productivity and desired product quality of the therapeutic monoclonal antibody (mAb) is one of the primary goals of process development. Across the various mAb programs at our company, we observed that increasing the specific productivity (qp) results in a decrease in the % galactosylation (%Gal) level on the protein. In order to gain further insight into this correlation, cells were cultured under different process conditions such as pH or media osmolality or in the presence of supplements such as sodium butyrate. A range of qp and N-glycan profiles were obtained with the greatest changes observed under high pH (lower qp, higher %Gal), higher osmolality (higher qp, lower %Gal) or sodium butyrate (moderately higher qp, moderately lower %Gal) conditions. Abundance of individual glycan species highlighted different bottlenecks in the N-glycosylation pathway depending on the treatment condition. Transcriptomics analysis was performed to identify changes in gene expression profiles that correlate with the inverse relationship between qp and %Gal. Results showed downregulation of Beta-1,4-galactosyltransferase 1 (B4GalT1), UDP-GlcNAc and Mn2+ transporter (slc35a3 and slc39a8 respectively) for the high osmolality conditions. Significant downregulation of slc39a8 (Mn2+ transporter) was observed for the sodium butyrate condition. No significant differences were observed for any of the genes in the N-glycosylation pathway under the high pH condition even though this condition showed highest %Gal. Together, data suggests that different treatments have distinct complex mechanisms by which the overall glycan levels of a mAb are influenced. Further studies based on these results will help build the knowledge necessary to design strategies to obtain the desired productivity and product quality of mAbs.
Collapse
Affiliation(s)
- Sri R Madabhushi
- Biologics Upstream Process Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
| | - Alexei A Podtelezhnikov
- Genetics and Pharmacogenomics, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Nicholas Murgolo
- Genetics and Pharmacogenomics, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Sen Xu
- Biologics Upstream Process Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| | - Henry Lin
- Biologics Upstream Process Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA
| |
Collapse
|
12
|
Comparison of Three Glycoproteomic Methods for the Analysis of the Secretome of CHO Cells Treated with 1,3,4- O-Bu 3ManNAc. Bioengineering (Basel) 2020; 7:bioengineering7040144. [PMID: 33182731 PMCID: PMC7712478 DOI: 10.3390/bioengineering7040144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 10/24/2020] [Accepted: 11/06/2020] [Indexed: 01/08/2023] Open
Abstract
Comprehensive analysis of the glycoproteome is critical due to the importance of glycosylation to many aspects of protein function. The tremendous complexity of this post-translational modification, however, makes it difficult to adequately characterize the glycoproteome using any single method. To overcome this pitfall, in this report we compared three glycoproteomic analysis methods; first the recently developed N-linked glycans and glycosite-containing peptides (NGAG) chemoenzymatic method, second, solid-phase extraction of N-linked glycoproteins (SPEG), and third, hydrophilic interaction liquid chromatography (HILIC) by characterizing N-linked glycosites in the secretome of Chinese hamster ovary (CHO) cells. Interestingly, the glycosites identified by SPEG and HILIC overlapped considerably whereas NGAG identified many glycosites not observed in the other two methods. Further, utilizing enhanced intact glycopeptide identification afforded by the NGAG workflow, we found that the sugar analog 1,3,4-O-Bu3ManNAc, a "high flux" metabolic precursor for sialic acid biosynthesis, increased sialylation of secreted proteins including recombinant human erythropoietin (rhEPO).
Collapse
|
13
|
Luo Y, Lovelett RJ, Price JV, Radhakrishnan D, Barnthouse K, Hu P, Schaefer E, Cunningham J, Lee KH, Shivappa RB, Ogunnaike BA. Modeling the Effect of Amino Acids and Copper on Monoclonal Antibody Productivity and Glycosylation: A Modular Approach. Biotechnol J 2020; 16:e2000261. [PMID: 32875683 DOI: 10.1002/biot.202000261] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 07/22/2020] [Indexed: 01/15/2023]
Abstract
In manufacturing monoclonal antibodies (mAbs), it is crucial to be able to predict how process conditions and supplements affect productivity and quality attributes, especially glycosylation. Supplemental inputs, such as amino acids and trace metals in the media, are reported to affect cell metabolism and glycosylation; quantifying their effects is essential for effective process development. We aim to present and validate, through a commercially relevant cell culture process, a technique for modeling such effects efficiently. While existing models can predict mAb production or glycosylation dynamics under specific process configurations, adapting them to new processes remains challenging, because it involves modifying the model structure and often requires some mechanistic understanding. Here, a modular modeling technique for adapting an existing model for a fed-batch Chinese hamster ovary (CHO) cell culture process without structural modifications or mechanistic insight is presented. Instead, data is used, obtained from designed experimental perturbations in media supplementation, to train and validate a supplemental input effect model, which is used to "patch" the existing model. The combined model can be used for model-based process development to improve productivity and to meet product quality targets more efficiently. The methodology and analysis are generally applicable to other CHO cell lines and cell types.
Collapse
Affiliation(s)
- Yu Luo
- University of Delaware, Chemical and Biomolecular Engineering, 150 Academy St, Newark, DE, 19716, USA
| | - Robert J Lovelett
- University of Delaware, Chemical and Biomolecular Engineering, 150 Academy St, Newark, DE, 19716, USA
| | - J Vincent Price
- Janssen Research and Development, Discovery, Product Development and Supply, 200 Great Valley Parkway, Malvern, PA, 19355, USA
| | - Devesh Radhakrishnan
- University of Delaware, Chemical and Biomolecular Engineering, 150 Academy St, Newark, DE, 19716, USA
| | - Kristopher Barnthouse
- Janssen Research and Development, Discovery, Product Development and Supply, 200 Great Valley Parkway, Malvern, PA, 19355, USA
| | - Ping Hu
- Janssen Research and Development, Discovery, Product Development and Supply, 200 Great Valley Parkway, Malvern, PA, 19355, USA
| | - Eugene Schaefer
- Janssen Research and Development, Discovery, Product Development and Supply, 200 Great Valley Parkway, Malvern, PA, 19355, USA
| | - John Cunningham
- Janssen Research and Development, Discovery, Product Development and Supply, 200 Great Valley Parkway, Malvern, PA, 19355, USA
| | - Kelvin H Lee
- University of Delaware, Chemical and Biomolecular Engineering, 150 Academy St, Newark, DE, 19716, USA
| | - Raghunath B Shivappa
- Takeda Pharmaceuticals, Biologics Process Development, 200 Shire Way, Lexington, MA, 02421, USA
| | - Babatunde A Ogunnaike
- University of Delaware, Chemical and Biomolecular Engineering, 150 Academy St, Newark, DE, 19716, USA
| |
Collapse
|
14
|
Markert S, Torkler S, Hohmann K, Popp O. Traces matter: Targeted optimization of monoclonal antibody N-glycosylation based on/by implementing automated high-throughput trace element screening. Biotechnol Prog 2020; 36:e3042. [PMID: 32583628 DOI: 10.1002/btpr.3042] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/17/2020] [Accepted: 06/18/2020] [Indexed: 01/02/2023]
Abstract
The use of high-throughput systems in cell culture process optimization offers various opportunities in biopharmaceutical process development. Here we describe the potential for acceleration and enhancement of product quality optimization and de novo bioprocess design regarding monoclonal antibody N-glycosylation by using an iterative statistical Design of Experiments (DoE) strategy based on our automated microtiter plate-based system for suspension cell culture. In our example, the combination of an initial screening of trace metal building blocks with a comprehensive DoE-based screening of 13 different trace elemental ions at three concentration levels in one run revealed most effective levers for N-glycan processing and biomass formation. Obtained results served to evaluate optimal concentration ranges and the right supplementation timing of relevant trace elements at shake flask and 2 L bioreactor scale. This setup identified manganese, copper, zinc, and iron as major factors. Manganese and copper acted as inverse key players in N-glycosylation, showing a positive effect of manganese and a negative effect of copper on glycan maturation in a zinc-dependent manner. Zinc and iron similarly improved cell growth and biomass formation. These findings allowed determining optimal concentration ranges for all four trace elements to establish control on desired product quality attributes regarding premature afucosylated and mature galactosylated glycan species. Our results demonstrates the power of combining robotics with DoE screening to enhance product quality optimization and to improve process understanding, thus, enabling targeted product quality control.
Collapse
Affiliation(s)
- Sven Markert
- Pharmaceutical Biotech Production and Development, Roche Diagnostics GmbH, Pharmaceutical Biotech Production and Development, Penzberg, Germany
| | - Stephanie Torkler
- Cell Culture Research, Roche Diagnostics GmbH, Cell Culture Research, Pharma Research and Early Development, Roche Innovation Center Munich, pRED, LMR, Penzberg, Germany
| | - Katharina Hohmann
- Cell Culture Research, Roche Diagnostics GmbH, Cell Culture Research, Pharma Research and Early Development, Roche Innovation Center Munich, pRED, LMR, Penzberg, Germany
| | - Oliver Popp
- Cell Culture Research, Roche Diagnostics GmbH, Cell Culture Research, Pharma Research and Early Development, Roche Innovation Center Munich, pRED, LMR, Penzberg, Germany
| |
Collapse
|
15
|
Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations. Antibodies (Basel) 2020; 9:antib9020022. [PMID: 32532067 PMCID: PMC7345016 DOI: 10.3390/antib9020022] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 05/29/2020] [Accepted: 06/03/2020] [Indexed: 12/12/2022] Open
Abstract
The development of recombinant therapeutic proteins has been a major revolution in modern medicine. Therapeutic-based monoclonal antibodies (mAbs) are growing rapidly, providing a potential class of human pharmaceuticals that can improve the management of cancer, autoimmune diseases, and other conditions. Most mAbs are typically of the immunoglobulin G (IgG) subclass, and they are glycosylated at the conserved asparagine position 297 (Asn-297) in the CH2 domain of the Fc region. Post-translational modifications here account for the observed high heterogeneity of glycoforms that may or not impact the stability, pharmacokinetics (PK), efficacy, and immunogenicity of mAbs. These modifications are also critical for the Fc receptor binding, and consequently, key antibody effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Moreover, mAbs produced in non-human cells express oligosaccharides that are not normally found in serum IgGs might lead to immunogenicity issues when administered to patients. This review summarizes our understanding of the terminal sugar residues, such as mannose, sialic acids, fucose, or galactose, which influence therapeutic mAbs either positively or negatively in this regard. This review also discusses mannosylation, which has significant undesirable effects on the PK of glycoproteins, causing a decreased mAbs’ half-life. Moreover, terminal galactose residues can enhance CDC activities and Fc–C1q interactions, and core fucose can decrease ADCC and Fc–FcγRs binding. To optimize the therapeutic use of mAbs, glycoengineering strategies are used to reduce glyco-heterogeneity of mAbs, increase their safety profile, and improve the therapeutic efficacy of these important reagents.
Collapse
|
16
|
A Reliable Automated Sampling System for On-Line and Real-Time Monitoring of CHO Cultures. Processes (Basel) 2020. [DOI: 10.3390/pr8060637] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Timely monitoring and control of critical process parameters and product attributes are still the basic tasks in bioprocess development. The current trend of automation and digitization in bioprocess technology targets an improvement of these tasks by reducing human error and increasing through-put. The gaps in such automation procedures are still the sampling procedure, sample preparation, sample transfer to analyzers, and the alignment of process and sample data. In this study, an automated sampling system and the respective data management software were evaluated for system performance; applicability with HPLC for measurement of vitamins, product and amino acids; and applicability with a biochemical analyzer. The focus was especially directed towards the adaptation and assessment of an appropriate amino acid method, as these substances are critical in cell culture processes. Application of automated sampling in a CHO fed-batch revealed its potential with regard to data evaluation. The higher sampling frequency compared to manual sampling increases the generated information content, which allows easier interpretation of the metabolism, extraction of e.g., ks values, application of smoothing algorithms, and more accurate detection of process events. A comparison with sensor technology shows the advantages and disadvantages in terms of measurement errors and measurement frequency.
Collapse
|
17
|
Fratz-Berilla EJ, Angart P, Graham RJ, Powers DN, Mohammad A, Kohnhorst C, Faison T, Velugula-Yellela SR, Trunfio N, Agarabi C. Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events. Biotechnol Bioeng 2020; 117:2802-2815. [PMID: 32436993 PMCID: PMC7496122 DOI: 10.1002/bit.27436] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 05/01/2020] [Accepted: 05/18/2020] [Indexed: 01/29/2023]
Abstract
A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell culture fluid. Previously, we reported a study regarding the ability of Mycoplasma arginini to persist in a single‐use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G 1 (IgG1) antibody. Our previous work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Careful evaluation of certain identified process parameters over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before detection from a traditional method. In this report, we studied the changes in the IgG1 product quality produced by CHO cells considered to be induced by the M. arginini contamination events. We observed changes in critical quality attributes correlated with the duration of contamination, including increased acidic charge variants and high mannose species, which were further modeled using principal component analysis to explore the relationships among M. arginini contamination, CHO cell growth and metabolites, and IgG1 product quality attributes. Finally, partial least square models using NIR spectral data were used to establish predictions of high levels (≥104 colony‐forming unit [CFU/ml]) of M. arginini contamination, but prediction of levels below 104 CFU/ml were not reliable. Contamination of CHO cells with M. arginini resulted in significant reduction of antibody product quality, highlighting the importance of rapid microbiological testing and mycoplasma testing during particularly long upstream bioprocesses to ensure product safety and quality.
Collapse
Affiliation(s)
- Erica J Fratz-Berilla
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| | - Phillip Angart
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| | - Ryan J Graham
- Division of Product Quality Research, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, Maryland.,Department of Chemical Engineering, University of Massachusetts Lowell, Lowell, Massachusetts
| | - David N Powers
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| | - Adil Mohammad
- Division of Product Quality Research, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Testing and Research, Silver Spring, Maryland
| | | | - Talia Faison
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| | - Sai Rashmika Velugula-Yellela
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| | | | - Cyrus Agarabi
- Division of Biotechnology Review and Research II, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Silver Spring, Maryland
| |
Collapse
|
18
|
Grinnell C, Bareford L, Matthews TE, Brantley T, Moore B, Kolwyck D. Elemental metal variance in cell culture raw materials for process risk profiling. Biotechnol Prog 2020; 36:e3004. [PMID: 32309907 DOI: 10.1002/btpr.3004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 02/18/2020] [Accepted: 04/16/2020] [Indexed: 12/28/2022]
Abstract
Elemental metals are critical raw material attributes which can impact cell culture performance and associated therapeutic protein product quality profiles. Metals such as copper and manganese act as cofactors and reagents for numerous metabolic pathways which govern cell growth, protein expression, and glycosylation, thus mandating elemental monitoring. The growing complexity of modern cell culture media formulations adds additional opportunities for elemental variance and its associated impact risks. This article describes an analytical technique applying inductively coupled plasma mass spectrometry to characterize a list of common raw materials and media powders used in mammalian cell culture and therapeutic protein production. We aim to describe a method qualification approach suitable for biopharmaceutical raw materials. Furthermore, we present detailed profiles of many common raw materials and discuss trends in raw material subtypes. Finally, a case study demonstrating the impact of an unexpected source of raw material variation is presented along with recommendations for raw material elemental risk profiling and control.
Collapse
Affiliation(s)
| | | | | | - Tim Brantley
- Cell Culture Development, Durham, North Carolina, USA
| | - Brandon Moore
- Cell Culture Development, Durham, North Carolina, USA
| | | |
Collapse
|
19
|
Bovine serum albumin affects N-glycoforms of murine IgG monoclonal antibody purified from hybridoma supernatants. Appl Microbiol Biotechnol 2020; 104:1583-1594. [PMID: 31915902 DOI: 10.1007/s00253-019-10309-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 11/25/2019] [Accepted: 12/08/2019] [Indexed: 12/11/2022]
Abstract
Immunoglobulin G (IgG) is a class of monoclonal antibodies (mAbs) commonly produced in mammalian cell lines. These cell lines are grown in finely adjusted culture media, which contain components that may impact glycoforms. As variation of N-glycoforms can impact the biological properties of IgGs, medium composition should be controlled. Here, we studied the effects on IgG N-glycoforms of different components in hybridoma culture media, specifically compared bovine serum albumin (BSA) with other small molecules, using a matrix-assisted laser desorption/ionization quadrupole ion trap time-of-flight multistage mass spectrometry (MALDI-QIT-TOF MSn)-based approach. We show that small molecular additives caused little change in glycan species, though a number of these reagents, especially glutamine, affected levels of glycosylation. In comparison, the addition of macromolecular protein BSA significantly changed IgG N-glycan patterns, not only in species but also in glycosylation levels. Together, our finding suggests that BSA increases the complexity of IgG N-glycoforms, thus raising the difficulty in maintaining glycoforms consistency during antibody production. Therefore, the effect of BSA on IgG N-glycans should be considered when designing optimal medium formulations for IgG production. KEY POINTS: • Small molecular medium additives only affect glycosylation levels of IgG N-glycans. • BSA significantly changes IgG N-glycoforms as a medium additive. • BSA's skewing of IgG N-glycoforms should be considered in IgG production.
Collapse
|
20
|
Knockout of sialidase and pro-apoptotic genes in Chinese hamster ovary cells enables the production of recombinant human erythropoietin in fed-batch cultures. Metab Eng 2019; 57:182-192. [PMID: 31785386 DOI: 10.1016/j.ymben.2019.11.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 11/20/2019] [Accepted: 11/24/2019] [Indexed: 12/13/2022]
Abstract
Sialic acid, a terminal monosaccharide present in N-glycans, plays an important role in determining both the in vivo half-life and the therapeutic efficacy of recombinant glycoproteins. Low sialylation levels of recombinant human erythropoietin (rhEPO) in recombinant Chinese hamster ovary (rCHO) cell cultures are considered a major obstacle to the production of rhEPO in fed-batch mode. This is mainly due to the accumulation of extracellular sialidases released from the cells. To overcome this hurdle, three sialidase genes (Neu1, 2, and 3) were initially knocked-out using the CRISPR/Cas9-mediated large deletion method in the rhEPO-producing rCHO cell line. Unlike wild type cells, sialidase knockout (KO) clones maintained the sialic acid content and proportion of tetra-sialylated rhEPO throughout fed-batch cultures without exhibiting a detrimental effect with respect to cell growth and rhEPO production. Additional KO of two pro-apoptotic genes, BAK and BAX, in sialidase KO clones (5X KO clones) further improved rhEPO production without any detrimental effect on sialylation. On day 10 in fed-batch cultures, the 5X KO clones had 1.4-times higher rhEPO concentration and 3.0-times higher sialic acid content than wild type cells. Furthermore, the proportion of tetra-sialylated rhEPO on day 10 in fed-batch cultures was 42.2-44.3% for 5X KO clones while it was only 2.2% for wild type cells. Taken together, KO of sialidase and pro-apoptotic genes in rCHO cells is a useful tool for producing heavily sialylated glycoproteins such as rhEPO in fed-batch mode.
Collapse
|
21
|
Sun Z, Ji Q, Evans AR, Lewis MJ, Mo J, Hu P. High-throughput LC-MS quantitation of cell culture metabolites. Biologicals 2019; 61:44-51. [DOI: 10.1016/j.biologicals.2019.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 07/29/2019] [Indexed: 10/26/2022] Open
|
22
|
Powers DN, Wang Y, Fratz-Berilla EJ, Velugula-Yellela SR, Chavez B, Angart P, Trunfio N, Yoon S, Agarabi C. Real-time quantification and supplementation of bioreactor amino acids to prolong culture time and maintain antibody product quality. Biotechnol Prog 2019; 35:e2894. [PMID: 31425633 PMCID: PMC7003473 DOI: 10.1002/btpr.2894] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 08/06/2019] [Accepted: 08/15/2019] [Indexed: 01/18/2023]
Abstract
Real‐time monitoring of cell cultures in bioreactors can enable expedited responses necessary to correct potential batch failure perturbations which may normally go undiscovered until the completion of the batch and result in failure. Currently, analytical technologies are dedicated to real‐time monitoring of bioreactor parameters such as pH, dissolved oxygen, and temperature, nutrients such as glucose and glutamine, or metabolites such as lactate. Despite the importance of amino acids as the building blocks of therapeutic protein products, other than glutamine their concentrations are not commonly measured. Here, we present a study into amino acid monitoring, supplementation strategies, and how these techniques may impact the cell growth profiles and product quality. We used preliminary bioreactor runs to establish baselines by determining initial amino acid consumption patterns, the results of which were used to select a pool of amino acids which gets depleted in the bioreactor. These amino acids were combined into blends which were supplemented into bioreactors during a subsequent run, the concentrations of which were monitored using a mass spectrometry based at‐line method we developed to quickly assess amino acid concentrations from crude bioreactor media. We found that these blends could prolong culture life, reversing a viable cell density decrease that was leading to batch death. Additionally, we assessed how these strategies might impact protein product quality, such as the glycan profile. The amino acid consumption data were aligned with the final glycan profiles in principal component analysis to identify which amino acids are most closely associated with glycan outcomes.
Collapse
Affiliation(s)
- David N Powers
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| | - Yifan Wang
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Testing and Research, Division of Product Quality Research, Silver Spring, Maryland
| | - Erica J Fratz-Berilla
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| | - Sai Rashmika Velugula-Yellela
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| | - Brittany Chavez
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| | - Phillip Angart
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| | - Nicholas Trunfio
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland.,Sartorius Stedim North America Inc, Corporate Research, Bohemia, NY
| | - Seongkyu Yoon
- Department of Chemical Engineering, University of Massachusetts, Lowell, Massachusetts
| | - Cyrus Agarabi
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, Maryland
| |
Collapse
|
23
|
Chen X, Liu X, Xiao Z, Liu J, Zhao L, Tan WS, Fan L. Insights into the loss of protein sialylation in an fc-fusion protein-producing CHO cell bioprocess. Appl Microbiol Biotechnol 2019; 103:4753-4765. [DOI: 10.1007/s00253-019-09850-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/09/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
|
24
|
Fisher AC, Kamga MH, Agarabi C, Brorson K, Lee SL, Yoon S. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing. Trends Biotechnol 2019; 37:253-267. [DOI: 10.1016/j.tibtech.2018.08.008] [Citation(s) in RCA: 81] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 08/20/2018] [Accepted: 08/29/2018] [Indexed: 01/19/2023]
|
25
|
Simonov V, Ivanov S, Smolov M, Abbasova S, Piskunov A, Poteryaev D. Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity. Biologicals 2019; 58:16-21. [DOI: 10.1016/j.biologicals.2019.01.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Revised: 12/04/2018] [Accepted: 01/02/2019] [Indexed: 01/08/2023] Open
|
26
|
Ehret J, Zimmermann M, Eichhorn T, Zimmer A. Impact of cell culture media additives on IgG glycosylation produced in Chinese hamster ovary cells. Biotechnol Bioeng 2019; 116:816-830. [PMID: 30552760 PMCID: PMC6590254 DOI: 10.1002/bit.26904] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 11/12/2018] [Accepted: 12/14/2018] [Indexed: 01/07/2023]
Abstract
Glycosylation is a key critical quality attribute for monoclonal antibodies and other recombinant proteins because of its impact on effector mechanisms and half‐life. In this study, a variety of compounds were evaluated for their ability to modulate glycosylation profiles of recombinant monoclonal antibodies produced in Chinese hamster ovary cells. Compounds were supplemented into the cell culture feed of fed‐batch experiments performed with a CHO K1 and a CHO DG44 cell line expressing a recombinant immunoglobulin G1 (IgG1). Experiments were performed in spin tubes or the ambr®15 controlled bioreactor system, and the impact of the compounds at various concentrations was determined by monitoring the glycosylation profile of the IgG and cell culture parameters, such as viable cell density, viability, and titer. Results indicate that the highest impact on mannosylation was achieved through 15 µM kifunensine supplementation leading to an 85.8% increase in high‐mannose containing species. Fucosylation was reduced by 76.1% through addition of 800 µM 2‐F‐peracetyl fucose. An increase of 40.9% in galactosylated species was achieved through the addition of 120 mM galactose in combination with 48 µM manganese and 24 µM uridine. Furthermore, 6.9% increased sialylation was detected through the addition of 30 µM dexamethasone in combination with the same manganese, uridine, and galactose mixture used to increase total galactosylation. Further compounds or combinations of additives were also efficient at achieving a smaller overall glycosylation modulation, required, for instance, during the development of biosimilars. To the best of our knowledge, no evaluation of the efficacy of such a variety of compounds in the same cell culture system has been described. The studied cell culture media additives are efficient modulators of glycosylation and are thus a valuable tool to produce recombinant glycoproteins.
Collapse
Affiliation(s)
- Janike Ehret
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany
| | - Martina Zimmermann
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany.,Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | | | - Aline Zimmer
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany
| |
Collapse
|
27
|
Dickens J, Khattak S, Matthews TE, Kolwyck D, Wiltberger K. Biopharmaceutical raw material variation and control. Curr Opin Chem Eng 2018. [DOI: 10.1016/j.coche.2018.10.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
28
|
Prabhu A, Gadgil M. Nickel and cobalt affect galactosylation of recombinant IgG expressed in CHO cells. Biometals 2018; 32:11-19. [PMID: 30327978 DOI: 10.1007/s10534-018-0152-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 09/28/2018] [Indexed: 11/27/2022]
Abstract
Glycosylation is an important product quality attribute of antibody biopharmaceuticals. It involves enzymatic addition of oligosaccharides on proteins by sequential action of glycosyltransferases and glycosidases in the endoplasmic reticulum and golgi. Some of these enzymes like galactosyltransferase and N-acetylglucosaminyltransferase-I require trace metal cofactors. Variations in trace metal availability during production can thus affect glycosylation of recombinant glycoproteins such as monoclonal antibodies. Variability in trace metal concentrations can be introduced at multiple stages during production such as due to impurities in raw materials for culture medium and leachables from bioreactors. Knowledge of the effect of various trace metals on glycosylation can help in root-cause analysis of unintended variability in glycosylation. In this study, we investigated the effect of nickel and cobalt on glycosylation of recombinant IgG expressed in Chinese hamster ovary cells. Nickel concentrations below 500 µM did not affect glycosylation, but above 500 µM it significantly decreases galactosylation of IgG. Cobalt at 50 µM concentration causes slight increase in G1F glycans (mono galactosylated) as previously reported. However, higher concentrations result in a small increase in G0F (non galactosylated) glycans. This effect of nickel and cobalt on galactosylation of recombinant IgG can be reversed by supplementation of uridine and galactose which are precursors to UDP-Galactose, a substrate for the enzymatic galactosylation reaction.
Collapse
Affiliation(s)
- Anuja Prabhu
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, 411008, India
| | - Mugdha Gadgil
- Chemical Engineering and Process Development Division, CSIR-National Chemical Laboratory, Pune, 411008, India.
| |
Collapse
|
29
|
Ritacco FV, Wu Y, Khetan A. Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies. Biotechnol Prog 2018; 34:1407-1426. [DOI: 10.1002/btpr.2706] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 08/03/2018] [Accepted: 08/06/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Frank V. Ritacco
- Biologics Process DevelopmentBristol‐Myers Squibb Pennington New Jersey United States
| | - Yongqi Wu
- Biologics Process DevelopmentBristol‐Myers Squibb Pennington New Jersey United States
| | - Anurag Khetan
- Biologics Process DevelopmentBristol‐Myers Squibb Pennington New Jersey United States
| |
Collapse
|
30
|
Chen X, Liu J, Liu X, Fan L, Zhao L, Tan WS. Characterization and minimization of sialic acid degradation in an Fc-fusion protein-producing CHO cell bioprocess. Process Biochem 2018. [DOI: 10.1016/j.procbio.2018.08.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Williamson J, Miller J, McLaughlin J, Combs R, Chu C. Scale‐dependent manganese leaching from stainless steel impacts terminal galactosylation in monoclonal antibodies. Biotechnol Prog 2018; 34:1290-1297. [DOI: 10.1002/btpr.2662] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 05/14/2018] [Indexed: 01/14/2023]
Affiliation(s)
- Jenna Williamson
- BioTherapeutics Pharmaceutical Sciences, Bioprocess Research & Development, Pfizer, Inc., 700 Chesterfield Parkway WestChesterfield MO 63017
| | - Jennifer Miller
- BioTherapeutics Pharmaceutical Sciences, Bioprocess Research & Development, Pfizer, Inc., 700 Chesterfield Parkway WestChesterfield MO 63017
| | - Joseph McLaughlin
- BioTherapeutics Pharmaceutical Sciences, Bioprocess Research & Development, Pfizer, Inc., 700 Chesterfield Parkway WestChesterfield MO 63017
| | - Rodney Combs
- BioTherapeutics Pharmaceutical Sciences, Bioprocess Research & Development, Pfizer, Inc., 700 Chesterfield Parkway WestChesterfield MO 63017
| | - Chia Chu
- BioTherapeutics Pharmaceutical Sciences, Bioprocess Research & Development, Pfizer, Inc., 700 Chesterfield Parkway WestChesterfield MO 63017
| |
Collapse
|
32
|
Blondeel EJM, Aucoin MG. Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions. Biotechnol Adv 2018; 36:1505-1523. [PMID: 29913209 DOI: 10.1016/j.biotechadv.2018.06.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 05/10/2018] [Accepted: 06/13/2018] [Indexed: 01/02/2023]
Abstract
Glycosylation is a critical quality attribute (CQA) of many therapeutic proteins, particularly monoclonal antibodies (mAbs), and is a major consideration in the approval of biosimilar biologics due to its effects to therapeutic efficacy. Glycosylation generates a distribution of glycoforms, resulting in glycoproteins with inherent molecule-to-molecule heterogeneity, capable of activating (or failing to activate) different effector functions of the immune system. Glycoforms can be affected by the supplementation of nucleotide-sugar precursors, and related components, to culture growth medium, affecting the metabolism of glycosylation. These supplementations has been demonstrated to increase nucleotide-sugar intracellular pools, and impact glycoform distributions, but with varied results. These variations can be attributed to five key factors: Differences between cell platforms (enzyme/transporter expression levels); differences between recombinant proteins produced (glycan-site accessibility); the fermentation and sampling timeline (glucose availability and exoglycosidase accumulation); glutamine levels (affecting ammonia levels, which impact Golgi pH, as well as UDP-GlcNAc pools); and finally, a lack of standardized metrics for observing shifts in glycoform distributions (glycosylation indices) across different experiments. The purpose of this review is to provide detail and clarity on the state of the art of supplementation strategies for nucleotide-sugar precursors for affecting glycosylation in cell culture processes, and to apply glycosylation indices for standardized comparisons across the field.
Collapse
Affiliation(s)
- Eric J M Blondeel
- Centre for Biotechnology and Bioengineering, Department of Chemical Engineering, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada
| | - Marc G Aucoin
- Centre for Biotechnology and Bioengineering, Department of Chemical Engineering, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada.
| |
Collapse
|
33
|
Characterizing the preparation of a concentrated nutrient feed solution for a large-scale cell culture process. Biochem Eng J 2018. [DOI: 10.1016/j.bej.2018.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
34
|
Chung S, Tian J, Tan Z, Chen J, Lee J, Borys M, Li ZJ. Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles. Biotechnol Bioeng 2018. [DOI: 10.1002/bit.26587] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Stanley Chung
- Department of Chemical Engineering; Northeastern University; Boston Massachusetts
| | - Jun Tian
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Zhijun Tan
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Jie Chen
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Jongchan Lee
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Michael Borys
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| |
Collapse
|
35
|
Popp O, Moser S, Zielonka J, Rüger P, Hansen S, Plöttner O. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function. MAbs 2017; 10:290-303. [PMID: 29173063 PMCID: PMC5825202 DOI: 10.1080/19420862.2017.1405203] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Novel biotherapeutic glycoproteins, like recombinant monoclonal antibodies (mAbs) are widely used for the treatment of numerous diseases. The N-glycans attached to the constant region of an antibody have been demonstrated to be crucial for the biological efficacy. Even minor modifications of the N-glycan structure can dictate the potency of IgG effector functions such as the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, we present the development of a glycoengineered CHO-K1 host cell line (HCL), stably expressing β1,4-N-Acetylglucoseaminyltransferase III (GnT-III) and α-mannosidase II (Man-II), for the expression of a-fucosylated antibodies with enhanced Fc-mediated effector function. Glycoengineered HCLs were generated in a two-step strategy, starting with generating parental HCLs by stable transfection of CHO-K1 cells with GnT-III and Man-II. In a second step, parental HCLs were stably transfected a second time with these two transgenes to increase their copy number in the genetic background. Generated glycoengineered CHO-K1 cell lines expressing two different mAbs deliver antibody products with a content of more than 60% a-fucosylated glycans. In-depth analysis of the N-glycan structure revealed that the majority of the Fc-attached glycans of the obtained mAbs were of complex bisected type. Furthermore, we showed the efficient use of FcγRIIIa affinity chromatography as a novel method for the fast assessment of the mAbs a-fucosylation level. By testing different cultivation conditions for the pre-glycoengineered recombinant CHO-K1 clones, we identified key components essential for the production of a-fucosylated mAbs. The prevalent effect could be attributed to the trace element manganese, which leads to a strong increase of a-fucosylated complex- and hybrid-type glycans. In conclusion, the novel pre-glycoengineered CHO-K1 HCL can be used for the production of antibodies with high ratios of a-fucosylated Fc-attached N-glycans. Application of our newly developed FcγRIIIa affinity chromatography method during cell line development and use of optimized cultivation conditions can ultimately support the efficient development of a-fucosylated mAbs.
Collapse
Affiliation(s)
- Oliver Popp
- a Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Munich , Nonnenwald 2, Penzberg , Germany
| | - Samuel Moser
- b Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Zurich , Wagistrasse 18, Schlieren , Switzerland
| | - Jörg Zielonka
- b Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Zurich , Wagistrasse 18, Schlieren , Switzerland
| | - Petra Rüger
- a Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Munich , Nonnenwald 2, Penzberg , Germany
| | - Silke Hansen
- a Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Munich , Nonnenwald 2, Penzberg , Germany
| | - Oliver Plöttner
- a Roche Pharma Research and Early Development , Large Molecule Research, Roche Innovation Center Munich , Nonnenwald 2, Penzberg , Germany
| |
Collapse
|
36
|
Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS. Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development. Front Immunol 2017; 8:1554. [PMID: 29181010 PMCID: PMC5693878 DOI: 10.3389/fimmu.2017.01554] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 10/31/2017] [Indexed: 11/23/2022] Open
Abstract
Monoclonal antibody (mAb)-based therapeutics are the fastest growing class of human pharmaceuticals. They are typically IgG1 molecules with N-glycans attached to the N297 residue on crystallizable fragment (Fc). Different Fc glycoforms impact their effector function, pharmacokinetics, stability, aggregation, safety, and immunogenicity. Fc glycoforms affect mAbs effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by modulating the Fc-FcγRs and Fc-C1q interactions. While the terminal galactose enhances CDC activity, the fucose significantly decreases ADCC. Defucosylated immunoglobulin Gs (IgGs) are thus highly pursued as next-generation therapeutic mAbs with potent ADCC at reduced doses. A plethora of cell glycoengineering and chemoenzymatic glycoengineering strategies is emerging to produce IgGs with homogenous glycoforms especially without core fucose. The chemoenzymatic glycosylation remodeling also offers useful avenues for site-specific conjugations of small molecule drugs onto mAbs. Herein, we review the current progress of IgG-Fc glycoengineering. We begin with the discussion of the structures of IgG N-glycans and biosynthesis followed by reviewing the impact of IgG glycoforms on antibody effector functions and the current Fc glycoengineering strategies with emphasis on Fc defucosylation. Furthermore, we briefly discuss two novel therapeutic mAbs formats: aglycosylated mAbs and Fc glycan specific antibody-drug conjugates (ADCs). The advances in the understanding of Fc glycobiology and development of novel glycoengineering technologies have facilitated the generation of therapeutic mAbs with homogenous glycoforms and improved therapeutic efficacy.
Collapse
Affiliation(s)
- Wei Li
- Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
| | - Zhongyu Zhu
- Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
| | - Weizao Chen
- Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
| | - Yang Feng
- Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
| | - Dimiter S. Dimitrov
- Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
| |
Collapse
|
37
|
Karengera E, Durocher Y, De Crescenzo G, Henry O. Combining metabolic and process engineering strategies to improve recombinant glycoprotein production and quality. Appl Microbiol Biotechnol 2017; 101:7837-7851. [PMID: 28924963 DOI: 10.1007/s00253-017-8513-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Revised: 08/15/2017] [Accepted: 09/02/2017] [Indexed: 11/28/2022]
Abstract
Increasing recombinant protein production while ensuring a high and consistent protein quality remains a challenge in mammalian cell culture process development. In this work, we combined a nutrient substitution approach with a metabolic engineering strategy that improves glucose utilization efficiency. This combination allowed us to tackle both lactate and ammonia accumulation and investigate on potential synergistic effects on protein production and quality. To this end, HEK293 cells overexpressing the pyruvate yeast carboxylase (PYC2) and their parental cells, both stably producing the therapeutic glycoprotein interferon α2b (IFNα2b), were cultured in media deprived of glutamine but containing chosen substitutes. Among the tested substitutes, pyruvate led to the best improvement in growth (integral of viable cell density) for both cell lines in batch cultures, whereas the culture of PYC2 cells without neither glutamine nor any substitute displayed surprisingly enhanced IFNα2b production. The drastic reduction in both lactate and ammonia in the cultures translated into extended high viability conditions and an increase in recombinant protein titer by up to 47% for the parental cells and the PYC2 cells. Product characterization performed by surface plasmon resonance biosensing using Sambucus nigra (SNA) lectin revealed that the increase in yield was however accompanied by a reduction in the degree of sialylation of the product. Supplementing cultures with glycosylation precursors and a cofactor were effective at counterbalancing the lack of glutamine and allowed improvement in IFNα2b quality as evaluated by lectin affinity. Our study provides a strategy to reconcile protein productivity and quality and highlights the advantages of PYC2-overexpressing cells in glutamine-free conditions.
Collapse
Affiliation(s)
- Eric Karengera
- Department of Chemical Engineering, École Polytechnique de Montréal, P.O. Box 6079, Succ. Centre-Ville, Montreal, QC, H3C 3A7, Canada
| | - Yves Durocher
- Human Health Therapeutics Portfolio, National Research Council Canada, Montreal, Canada
| | - Gregory De Crescenzo
- Department of Chemical Engineering, École Polytechnique de Montréal, P.O. Box 6079, Succ. Centre-Ville, Montreal, QC, H3C 3A7, Canada
| | - Olivier Henry
- Department of Chemical Engineering, École Polytechnique de Montréal, P.O. Box 6079, Succ. Centre-Ville, Montreal, QC, H3C 3A7, Canada.
| |
Collapse
|
38
|
Huang Z, Lee DY, Yoon S. Quantitative intracellular flux modeling and applications in biotherapeutic development and production using CHO cell cultures. Biotechnol Bioeng 2017; 114:2717-2728. [DOI: 10.1002/bit.26384] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 06/07/2017] [Accepted: 07/12/2017] [Indexed: 12/23/2022]
Affiliation(s)
- Zhuangrong Huang
- Department of Chemical Engineering, University of Massachusetts Lowell; One University Avenue; Lowell Massachusetts
| | - Dong-Yup Lee
- Department of Chemical and Biomolecular Engineering; National University of Singapore; Singapore Singapore
- Bioprocessing Technology Institute; Agency for Science, Technology and Research (A*STAR); Singapore Singapore
| | - Seongkyu Yoon
- Department of Chemical Engineering, University of Massachusetts Lowell; One University Avenue; Lowell Massachusetts
| |
Collapse
|
39
|
Torkashvand F, Vaziri B. Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. IRANIAN BIOMEDICAL JOURNAL 2017; 21:131-41. [PMID: 28176518 PMCID: PMC5392216 DOI: 10.18869/acadpub.ibj.21.3.131] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 11/05/2016] [Accepted: 11/08/2016] [Indexed: 11/09/2022]
Abstract
The culture media optimization is an inevitable part of upstream process development in therapeutic monoclonal antibodies (mAbs) production. The quality by design (QbD) approach defines the assured quality of the final product through the development stage. An important step in QbD is determination of the main quality attributes. During the media optimization, some of the main quality attributes such as glycosylation pattern, charge variants, aggregates, and low-molecular-weight species, could be significantly altered. Here, we provide an overview of how cell culture medium components affects the main quality attributes of the mAbs. Knowing the relationship between the culture media components and the main quality attributes could be successfully utilized for a rational optimization of mammalian cell culture media for industrial mAbs production.
Collapse
Affiliation(s)
| | - Behrouz Vaziri
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
40
|
Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles. Biotechnol Prog 2017; 33:511-522. [DOI: 10.1002/btpr.2429] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 12/10/2016] [Indexed: 11/07/2022]
|
41
|
Fan Y, Kildegaard HF, Andersen MR. Engineer Medium and Feed for Modulating N-Glycosylation of Recombinant Protein Production in CHO Cell Culture. Methods Mol Biol 2017; 1603:209-226. [PMID: 28493133 DOI: 10.1007/978-1-4939-6972-2_14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Chinese hamster ovary (CHO) cells have become the primary expression system for the production of complex recombinant proteins due to their long-term success in industrial scale production and generating appropriate protein N-glycans similar to that of humans. Control and optimization of protein N-glycosylation is crucial, as the structure of N-glycans can largely influence both biological and physicochemical properties of recombinant proteins. Protein N-glycosylation in CHO cell culture can be controlled and tuned by engineering medium, feed, culture process, as well as genetic elements of the cell. In this chapter, we will focus on how to carry out experiments for N-glycosylation modulation through medium and feed optimization. The workflow and typical methods involved in the experiment process will be presented.
Collapse
Affiliation(s)
- Yuzhou Fan
- Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark.
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
| | - Helene Faustrup Kildegaard
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | | |
Collapse
|
42
|
Batra J, Rathore AS. Glycosylation of monoclonal antibody products: Current status and future prospects. Biotechnol Prog 2016; 32:1091-1102. [DOI: 10.1002/btpr.2366] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 09/04/2016] [Indexed: 12/31/2022]
Affiliation(s)
- Jyoti Batra
- Department of Chemical Engineering; Indian Institute of Technology; Hauz Khas New Delhi India
| | - Anurag S. Rathore
- Department of Chemical Engineering; Indian Institute of Technology; Hauz Khas New Delhi India
| |
Collapse
|
43
|
Saito F, Sakamoto I, Kanatani A, Chiba Y. Manganese ion concentration affects production of human core 3 O-glycan in Saccharomyces cerevisiae. Biochim Biophys Acta Gen Subj 2016; 1860:1809-20. [PMID: 27259834 DOI: 10.1016/j.bbagen.2016.05.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 05/23/2016] [Accepted: 05/28/2016] [Indexed: 01/25/2023]
Abstract
BACKGROUND Production of various mucin-like glycoproteins could be useful for development of antibodies specific to disease-related glycoproteins as well as for the biosynthesis of clinically useful glycoproteins. A Saccharomyces cerevisiae strain capable of in vivo production of mucin-type core 1 structure (Galβ1-3GalNAcα1-O-Ser/Thr) has been reported, but a strain producing core 3 structure (GlcNAcβ1-3GalNAcα1-O-Ser/Thr) has not been constructed. METHODS To generate core 3-producing strain, genes encoding uridine diphosphate (UDP)-Gal-4-epimerase, UDP-GalNAc transporter, UDP-GlcNAc transporter, and two glycosyltransferases were integrated into the genome. A Mucin-1-derived acceptor peptide (MUC1ap) was expressed as an acceptor. The amount of the resulting modified peptide was analyzed by HPLC. RESULTS Introduction of a codon-optimized UDP-GlcNAc:βGal β-1,3-N-acetylglucosaminyltransferase 6 (β3Gn-T6) gene yielded increases in β3Gn-T6 activity but did not alter the level of core 3 production. The highest in vitro activity of β3Gn-T6 was observed at Mn(2+) concentrations of 10mM and above. Supplementation of MnCl2 to the culture medium yielded increases of up to 25% in the accumulation of core 3 on the MUC1ap. The yeast invertase from the core 3-producing strain was less extensively N-glycosylated; however, it was partially restored by the addition of MnCl2 to the medium. CONCLUSIONS Physiological Mn(2+) concentration in S. cerevisiae was insufficient to facilitate optimal synthesis of core 3. Mn(2+) supplementation led to up-regulation of reaction of glycosylation in the Golgi, resulting in increases of core 3 production. GENERAL SIGNIFICANCE This study reveals that control of Mn(2+) concentration is important for production of specific mammalian-type glycans in S. cerevisiae.
Collapse
Affiliation(s)
- Fumie Saito
- Biotechnology Research Institute for Drug Discovery, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan; GlycoGene Inc., Avenue Takanawa Rm. 412, 3-25-27, Takanawa, Minato-ku, Tokyo 108-0074, Japan
| | - Izumi Sakamoto
- AcroScale Inc., 3-8-1 Kokubun-cho, Aoba-ku, Sendai, Miyagi 980-0803, Japan
| | - Akio Kanatani
- GlycoGene Inc., Avenue Takanawa Rm. 412, 3-25-27, Takanawa, Minato-ku, Tokyo 108-0074, Japan
| | - Yasunori Chiba
- Biotechnology Research Institute for Drug Discovery, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan.
| |
Collapse
|
44
|
Sha S, Agarabi C, Brorson K, Lee DY, Yoon S. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies. Trends Biotechnol 2016; 34:835-846. [PMID: 27016033 DOI: 10.1016/j.tibtech.2016.02.013] [Citation(s) in RCA: 99] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 02/20/2016] [Accepted: 02/24/2016] [Indexed: 12/31/2022]
Abstract
The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly affect antibody biological functions and are largely determined by host cell genotypes and culture conditions. A key step in bioprocess development for monoclonal antibodies (mAbs) involves optimization and control of N-glycan profiles. With pressure from pricing and biosimilars looming, more efficient and effective approaches are sought in the field of glycoengineering. Metabolic studies and mathematical modeling are two such approaches that optimize bioprocesses by better understanding and predicting glycosylation. In this review, we summarize a group of strategies currently used for glycan profile modulation and control. Metabolic analysis and mathematical modeling are then explored with an emphasis on how these two techniques can be utilized to advance glycoengineering.
Collapse
Affiliation(s)
- Sha Sha
- Biomedical Engineering and Biotechnology, University of Massachusetts Lowell, Lowell, MA 01850, USA
| | - Cyrus Agarabi
- Division of Biotechnology Review and Research II, Office of Biotechnology Products, OPQ, CDER, FDA, Silver Spring, MD, USA
| | - Kurt Brorson
- Division of Biotechnology Review and Research II, Office of Biotechnology Products, OPQ, CDER, FDA, Silver Spring, MD, USA
| | - Dong-Yup Lee
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive, Singapore 117585, Singapore
| | - Seongkyu Yoon
- Biomedical Engineering and Biotechnology, University of Massachusetts Lowell, Lowell, MA 01850, USA.
| |
Collapse
|
45
|
Slade PG, Caspary RG, Nargund S, Huang CJ. Mannose metabolism in recombinant CHO cells and its effect on IgG glycosylation. Biotechnol Bioeng 2016; 113:1468-80. [PMID: 26724786 DOI: 10.1002/bit.25924] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Revised: 11/24/2015] [Accepted: 12/28/2015] [Indexed: 01/02/2023]
Abstract
Understanding the causes of high-mannose (HM) glycosylation of recombinant IgG in CHO cells would facilitate the production of therapeutics. CHO cells grown with mannose as the major carbon source demonstrated a dramatic increase in total HM glycosylation in recombinant IgG, with no effect on cell growth, viability, or titer. Quantitative metabolomics and (13) C flux analysis were used to explore the mechanism for increased HM glycosylation and understand the metabolism of mannose in CHO cells. It was demonstrated that mannose was a good carbon source for CHO cell growth and IgG production, readily entering both glycolysis and the TCA Cycle. Previous mechanisms for increased HM glycosylation during antibody production have been attributed to changes in pH, osmolality, increased specific productivity, and nutrient limitation. The results from this study propose a novel mechanism where an increased carbon flux in the GDP-mannose synthetic pathway increased the intracellular concentration of mannose-containing metabolites. The abnormally high concentration of mannose and mannose-metabolites were shown to inhibit α-mannosidase activity and it was proposed that this inhibition in the ER and Golgi caused the production of IgG with increased high-mannose glycosylation. Biotechnol. Bioeng. 2016;113: 1468-1480. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Peter G Slade
- Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, 98119, Washington.
| | - R Guy Caspary
- Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, 98119, Washington
| | - Shilpa Nargund
- Process and Product Development, Amgen Inc., Thousand Oaks, California
| | - Chung-Jr Huang
- Process and Product Development, Amgen Inc., Thousand Oaks, California
| |
Collapse
|
46
|
Park JH, Noh SM, Woo JR, Kim JW, Lee GM. Valeric acid induces cell cycle arrest at G1 phase in CHO cell cultures and improves recombinant antibody productivity. Biotechnol J 2015; 11:487-96. [PMID: 26663903 DOI: 10.1002/biot.201500327] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 08/22/2015] [Accepted: 12/10/2015] [Indexed: 01/18/2023]
Abstract
To find a more effective chemical reagent for improved monoclonal antibody (mAb) production, eight chemical reagents (curcumin, quercein, DL-sulforaphane, thymidine, valeric acid, phenyl butyrate, valproic acid, and lithium chloride) known to induce cell cycle arrest were examined individually as chemical additives to recombinant CHO (rCHO) cell cultures producing mAb. Among these chemical additives, valeric acid showed the best production performance. Valeric acid decreased specific growth rate (μ), but increased culture longevity and specific mAb productivity (qmAb ) in a dose-dependent manner. The beneficial effect of valeric acid on culture longevity and qmAb outweighed its detrimental effect on μ, resulting in 2.9-fold increase in the maximum mAb concentration when 1.5 mM valeric acid was added to the cultures. Furthermore, valeric acid did not negatively affect the mAb quality attributes with regard to aggregation, charge variation, and galactosylation. Unexpectedly, galactosylation of the mAb increased by the 1.5 mM valeric acid addition. Taken together, the results obtained here demonstrate that valeric acid is an effective chemical reagent to increase mAb production in rCHO cells.
Collapse
Affiliation(s)
- Jin Hyoung Park
- Department of Biological Sciences, KAIST, Daejeon, Republic of Korea
| | - Soo Min Noh
- Department of Biological Sciences, KAIST, Daejeon, Republic of Korea
| | - Ju Rang Woo
- New Drug Development Center, Cheongju, Republic of Korea
| | - Jong Won Kim
- New Drug Development Center, Cheongju, Republic of Korea
| | - Gyun Min Lee
- Department of Biological Sciences, KAIST, Daejeon, Republic of Korea.
| |
Collapse
|
47
|
Markely LRA, Cheung L, Choi YJ, Ryll T, Estes S, Prajapati S, Turyan I, Frenkel R, Sosic Z, Lambropoulos J, Tescione L, Ryll T, Berman M. A high-throughput capillary isoelectric focusing immunoassay for fingerprinting protein sialylation. Biotechnol Prog 2015; 32:235-41. [DOI: 10.1002/btpr.2206] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Revised: 09/15/2015] [Indexed: 12/14/2022]
Affiliation(s)
- Lam Raga Anggara Markely
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Lila Cheung
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Young Jun Choi
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Thomas Ryll
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Scott Estes
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Shashi Prajapati
- Cell Culture Development-High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Iva Turyan
- Analytical Development - High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Ruth Frenkel
- Analytical Development - High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | - Zoran Sosic
- Analytical Development - High-Throughput Analytical Group; Biogen, 125 Broadway Cambridge MA 02142
| | | | - Lia Tescione
- Cell Culture Development; Biogen, 125 Broadway Cambridge MA 02142
| | - Thomas Ryll
- Cell Culture Development; Biogen, 125 Broadway Cambridge MA 02142
| | - Melissa Berman
- Biomolecular and Small Molecule Science; Biogen, 125 Broadway Cambridge MA 02142
| |
Collapse
|
48
|
Hazeltine LB, Knueven KM, Zhang Y, Lian Z, Olson DJ, Ouyang A. Chemically defined media modifications to lower tryptophan oxidation of biopharmaceuticals. Biotechnol Prog 2015; 32:178-88. [PMID: 26560440 DOI: 10.1002/btpr.2195] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 10/16/2015] [Indexed: 12/16/2022]
Abstract
Oxidation of biopharmaceuticals is a major product quality issue with potential impacts on activity and immunogenicity. At Eli Lilly and Company, high tryptophan oxidation was observed for two biopharmaceuticals in development produced in Chinese hamster ovary cells. A switch from historical hydrolysate-containing media to chemically defined media with a reformulated basal powder was thought to be responsible, so mitigation efforts focused on media modification. Shake flask studies identified that increasing tryptophan, copper, and manganese and decreasing cysteine concentrations were individual approaches to lower tryptophan oxidation. When amino acid and metal changes were combined, the modified formulation had a synergistic impact that led to substantially less tryptophan oxidation for both biopharmaceuticals. Similar results were achieved in shake flasks and benchtop bioreactors, demonstrating the potential to implement these modifications at manufacturing scale. The modified formulation did not negatively impact cell growth and viability, product titer, purity, charge variants, or glycan profile. A potential mechanism of action is presented for each amino acid or metal factor based on its role in oxidation chemistry. This work served not only to mitigate the tryptophan oxidation issue in two Lilly biopharmaceuticals in development, but also to increase our knowledge and appreciation for the impact of media components on product quality.
Collapse
Affiliation(s)
- Laurie B Hazeltine
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| | - Kristine M Knueven
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| | - Yan Zhang
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| | - Zhirui Lian
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| | - Donald J Olson
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| | - Anli Ouyang
- Bioproduct Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285
| |
Collapse
|
49
|
Zupke C, Brady LJ, Slade PG, Clark P, Caspary RG, Livingston B, Taylor L, Bigham K, Morris AE, Bailey RW. Real-time product attribute control to manufacture antibodies with defined N-linked glycan levels. Biotechnol Prog 2015; 31:1433-41. [PMID: 26179435 DOI: 10.1002/btpr.2136] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 06/15/2015] [Indexed: 01/11/2023]
Affiliation(s)
- Craig Zupke
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Lowell J. Brady
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Peter G. Slade
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Philip Clark
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - R. Guy Caspary
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Brittney Livingston
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Lisa Taylor
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Kyle Bigham
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Arvia E. Morris
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| | - Robert W. Bailey
- Product and Process Development; Amgen Inc.; 1201 Amgen Court West Seattle WA 98119
| |
Collapse
|
50
|
Chumsae C, Hossler P, Raharimampionona H, Zhou Y, McDermott S, Racicot C, Radziejewski C, Zhou ZS. When Good Intentions Go Awry: Modification of a Recombinant Monoclonal Antibody in Chemically Defined Cell Culture by Xylosone, an Oxidative Product of Ascorbic Acid. Anal Chem 2015; 87:7529-34. [DOI: 10.1021/acs.analchem.5b00801] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Chris Chumsae
- Protein
Analytics, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
- Barnett
Institute of Chemical and Biological Analysis, Department of Chemistry
and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States
| | - Patrick Hossler
- Cell
Culture, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Haly Raharimampionona
- Protein
Analytics, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Yu Zhou
- Protein
Analytics, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Sean McDermott
- Cell
Culture, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Chris Racicot
- Cell
Culture, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Czeslaw Radziejewski
- Protein
Analytics, Process Sciences Department, AbbVie Bioresearch Center, Worcester, Massachusetts 01605, United States
| | - Zhaohui Sunny Zhou
- Barnett
Institute of Chemical and Biological Analysis, Department of Chemistry
and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States
| |
Collapse
|